Skip to main content

Nautilus Biotechnology, Inc.

NAUT
Exchange
Nasdaq
Industry
Laboratory Analytical Instruments
SEC CIK
0001808805

No open-market purchases or sales by Nautilus Biotechnology, Inc. insiders were filed in the last 90 days; 93 institutions reported holding it in 13F filings for Q2 2026, worth $93.7M in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Nautilus Biotechnology, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of NAUT: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders8182+1
Shares59.6M56.0M−3.54M (−5.9%)
Value$234.8M$243.5M+$8.74M (+3.7%)

New holders (17)

Institutions that held Nautilus Biotechnology, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to NAUT in Q1 2022
InstitutionSharesValue% of portfolio
Decheng Capital Management III (Cayman), LLC300,000$1.30M0.40%
ExodusPoint Capital Management, LP137,826$598.0K0.01%
HRT Financial LP111,158$482.0K0.00%
Sentinel Trust Co Lba85,000$369.0K0.04%
Sciencast Management LP63,529$283.0K0.06%
Bank of Montreal62,000$270.0K0.00%
Squarepoint Ops LLC42,626$185.0K0.00%
Barclays PLC41,516$180.0K0.00%
Balyasny Asset Management LLC29,212$127.0K0.00%
CAPROCK Group, Inc.24,790$108.0K0.01%
Y-Intercept (Hong Kong) Ltd16,106$70.0K0.02%
Schonfeld Strategic Advisors LLC13,211$57.0K0.00%
Renaissance Technologies LLC11,000$48.0K0.00%
HB Wealth Management, LLC11,037$48.0K0.00%
Fifth Lane Capital, LP10,200$44.0K0.03%
Royal Bank of Canada2,097$9.00K0.00%
Ovata Capital Management Ltd600$3.00K0.00%

Sold out (16)

Institutions that held Nautilus Biotechnology, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.